^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD166-targeted antibody-drug conjugate

    Related drugs:
    28d
    Defining the functional role and potential as an immunotherapeutic target of ALCAM in neuroblastoma. (PubMed, Mol Cancer Ther)
    Treatment with the MYC(N)/MAX dimerization inhibitor MYCi975 reduced ALCAM expression by immunoblotting and luciferase signal from the ALCAM promoter. Finally, as ALCAM is expressed in several normal tissues, we investigated an ALCAM-targeted conditionally activated antibody drug conjugate (ADC), CX-2009 (praluzatamab ravtansine), which delayed tumor growth in two out of three PDX models. Together, these findings credential ALCAM as an immunotherapeutic target in neuroblastoma.
    Journal • PARP Biomarker • IO biomarker
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • ALCAM (Activated Leukocyte Cell Adhesion Molecule)
    |
    MYCi975 • praluzatamab ravtansine (CX-2009)
    almost2years
    CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=125, Completed, CytomX Therapeutics | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
    almost2years
    PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors (clinicaltrials.gov)
    P1/2, N=99, Terminated, CytomX Therapeutics | Completed --> Terminated; Covid Pandemic; Business Decision to separate Phase 2 to new study
    Trial termination • Metastases
    |
    praluzatamab ravtansine (CX-2009)
    almost3years
    CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, CytomX Therapeutics | Trial completion date: Sep 2023 --> Apr 2023 | Trial primary completion date: Sep 2023 --> Apr 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
    over3years
    CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, CytomX Therapeutics | Recruiting --> Active, not recruiting | N=200 --> 125
    Enrollment closed • Enrollment change • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
    over3years
    CTMX-2009-002: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, CytomX Therapeutics | N=150 --> 200 | Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
    almost4years
    Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial. (PubMed, Clin Cancer Res)
    CD166 is a novel, ubiquitously expressed target. CX-2009 is the first conditionally activated antibody-drug conjugate to CD166 to demonstrate both translational and clinical activity in a variety of tumor types.
    P1/2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive
    |
    praluzatamab ravtansine (CX-2009)
    4years
    Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab (SABCS 2021)
    This study will also evaluate safety and tolerability, pharmacokinetics, and antidrug antibodies with praluzatamab ravtansine as monotherapy and in combination with pacmilimab. This trial is enrolling (NCT04596150).
    Clinical • P2 data
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 amplification • PD-L1 negative
    |
    praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
    over4years
    [VIRTUAL] Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC) (ESMO-BC 2021)
    This study will also evaluate safety and tolerability, pharmacokinetics, and antidrug antibodies with CX-2009 as monotherapy and in combination with pacmilimab. This trial is enrolling (NCT04596150).
    Clinical • P2 data • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • PD-L1 negative
    |
    praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
    almost5years
    Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=150, Recruiting, CytomX Therapeutics | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
    5years
    Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, CytomX Therapeutics
    Clinical • New P2 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)
    5years
    [VIRTUAL] A Phase 2, open-label study to evaluate the safety and efficacy of the probody therapeutic (Pb-Tx) CX‑2009 in metastatic HR-Positive/HER2-negative breast cancer (mHR+/HER2− BC) and of CX-2009 as monotherapy and in combination therapy with CX-072 in metastatic triple-negative breast cancer (TNBC) (SABCS 2020)
    This trial is actively enrolling. Email address for questions or comments: gpaton@cytomx.com
    Clinical • P2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HER-2 expression • PD-L1 negative • HR positive + HER-2 negative
    |
    praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)